论文部分内容阅读
新型冠状病毒肺炎（COVID-19）疫情正面临着最危急的状况，截至2021年1月11日，全球确诊病例已近9 000万，死亡病例近200万。我国本土疫情呈零星散发和局部聚集性疫情交织叠加态势，防疫战疫形势严峻复杂。在这种形势下，患者的用药安全面临诸多问题，如COVID-19治疗的超说明书用药和同情用药中的安全问题、COVID-19治疗药物与其他疾病治疗药物并用中的安全问题、COVID-19治疗药物不良反应监测、公众自购药物预防和治疗COVID-19的安全问题以及疫情期间其他疾病患者用药的安全问题等。因此，需要对患者的用药安全问题给予更多关注，科学抗疫，用更小的代价去赢取COVID-19疫情防控阻击战的更大胜利。“,”The coronavirus disease 2019 (COVID-19) epidemic is facing the most critical situation. As of January 11, 2021, there have been nearly 90 million confirmed cases worldwide and nearly 2 million deaths. The local epidemic situation in China is sporadic and locally clustered, and the situation of epidemic prevention is difficult and complicated. In this situation, there are many problems in medication safety of patients, such as safety issues in off-label medication and compassionate medication of COVID-19 treatment, safety problems in the combination use of drugs for COVID-19 and drugs for other diseases, monitoring of adverse drug reactions in COVID-19 treatment, the safety issues in self-purchased drugs for prevention and treatment of COVID-19, and the medication safety in patients with other diseases during the epidemic. Therefore, it is necessary to pay more attention to the medication safety of patients to fight the epidemic scientifically and to win a greater victory in the fight against the COVID-19 epidemic at a smaller price.